

PCT

EP 0575432
WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : A61K 37/02, C07K 3/08, 15/00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 92/15316 (43) International Publication Date: 17 September 1992 (17.09.92)</p>
<p>(21) International Application Number: PCT/NL92/00036 (22) International Filing Date: 24 February 1992 (24.02.92) (30) Priority data: 9100434 11 March 1991 (11.03.91) NL (71) Applicant (for all designated States except US): RIJKSUNIVERSITEIT TE GRONINGEN [NL/NL]; P.O. Box 72, NL-9700 AB Groningen (NL). (72) Inventors; and (75) Inventors/Applicants (for US only): JANSEN, Robert, Walter [NL/NL]; Turfsingel 8A, NL-9712 KP Groningen (NL). MEIJER, Dirk, Klaas, Fokke [NL/NL]; Parklaan 17, NL-9724 AN Groningen (NL). MOLEMA, Grietje [NL/NL]; E. Th. A. Thuessinklaan 32A, NL-9713 JV Groningen (NL). DE CLERCQ, Erik, Désiré, Alice [BE/BE]; Parklaan 9, B-3360 Lovenjoel (BE). PAUWELS, Rudi, Wilfried, Jan [BE/BE]; Damstraat 166, B-1982 Weerde (BE). SCHOLS, Dominique [BE/BE]; Zevenslaersstraat 18, B-3000 Leuven (BE).</p>		<p>(74) Agent: DE BRUIJN, Leendert, C.; Nederlandsch Octrooibureau, Scheveningseweg 82, P.O. Box 29720, NL-2502 LS The Hague (NL). (81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE, DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC (European patent), MG, ML (OAPI patent), MN, MR (OAPI patent), MW, NL, NL (European patent), NO, PL, RO, RU, SD, SE, SE (European patent), SN (OAPI patent), TD (OAPI patent), TG (OAPI patent), US. Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments. In English translation (filed in Dutch).</i></p>
<p>(54) Title: MODIFIED PROTEINS AND THEIR USE FOR CONTROLLING VIRAL INFECTIONS</p> <p>(57) Abstract</p> <p>The invention relates to pharmaceutical preparations which are suitable for treating or curing viral infections, including influenza and immunodeficiency diseases such as retrovirus infections, including AIDS and AIDS-related diseases, and which can also be used to inhibit fusion of virus-infected cells with non-infected cells, which preparations contain modified proteins or polypeptides as active substance or substance contributing to the action or as carrier for other substances, which are also active, which modified proteins or polypeptides have acquired an additional net negative charge by derivatisation of their amino groups and/or other basic functional groups with a reagent which prevents protonation of basic amino acids and/or other basic functional groups or replaces said basic amino acids and/or other basic functional groups by one or more functional groups having a negative charge, and to modified proteins and polypeptides themselves and the preparation and use thereof.</p>		

MODIFIED PROTEINS AND THEIR USE FOR CONTROLLING VIRAL INFECTIONS

5 The invention relates to pharmaceutical preparations which are suitable for treating or curing viral infections, including influenza and immunodeficiency diseases such as retrovirus infections, including AIDS and AIDS-related diseases, and which can also be used to inhibit fusion of virus-infected cells with non-
10 infected cells, which preparations contain modified proteins or polypeptides as active substance or substance contributing to the action or as carrier for other substances, which are also active.

 The use of glycoproteins as cell-specific carriers for 3'-azido-3'-desoxythymidine (AZT) is disclosed in the publication by
15 Molema, G., Jansen, R.W., Pauwels, R., De Clerq, E., and Meijer, D.K.F. in Biochem. Pharmacol. part 40, No. 12, pp. 2603-2610 (1990). To date AZT is the only registered agent for the treatment of AIDS. AZT blocks the synthesis of viral DNA in the infected cells. Although AIDS is not cured, the agent prolongs life expectancy.
20 Unfortunately, AZT also attacks healthy cells and therefore gives rise to a large number of undesirable side effects. These side effects arise in particular in tissues where a large amount of DNA is produced, for example in bone marrow. According to the above-mentioned publication, it is proposed to direct AZT to target cells
25 with the aid of a carrier molecule. According to the abovementioned publication, conjugates of albumin (HSA) and sugars, for example mannose, fucose, galactose and glucose, are prepared and tested for their anti-HIV activity in combination with AZTMP (AZT phosphorylated to the monophosphate form). It is presumed that the carrier
30 molecule releases the active substance once the conjugate of glycoprotein and active substance has been absorbed by the target cell.

 The use of sulphated phenyl polymers in preparations for the treatment of retrovirus infections is disclosed in Netherlands Patent Application 8900442. Sulphated phenyl polymers mentioned in
35 this publication are sulphated polyphenyl alcohols, sulphated copolymers of (meth)acrylic acid and phenyl alcohol and pharmaceutically acceptable salts thereof. These active substances reduce the

cytopathogenicity of HIV-1 in MT-4 cells and the antigen expression of HIV-1 in CEM cells. They are also active against the replication of HIV-2. In addition, the formation of giant cells (multinuclear syncytium cells), generated by HIV-1, and the adsorption of HIV fragments on CD-4 positive cells are inhibited.

The invention relates to pharmaceutical preparations which are suitable for treating or curing viral infections and immunodeficiency diseases such as retrovirus infections, including AIDS and AIDS-related diseases, and which can also be used to inhibit fusion of virus-infected cells with non-infected cells, which preparations contain modified proteins or polypeptides as active substance or substance contributing to the action or as carrier for other substances, which are also active, which modified proteins or polypeptides have acquired an additional net negative charge by derivatisation of their amino groups and/or other basic functional groups with a reagent which prevents protonation of basic amino acids and/or other basic functional groups or replaces said basic amino acids and/or other basic functional groups by one or more functional groups having a negative charge, the prolongation of the retention time of the protein or polypeptide derivative compared with that of the protein or polypeptide not converted to a derivative being at least 9 minutes, the retention time being determined by means of FPLC on an anion exchange column.

The present invention is based on the finding that a correlation exists between the negative charge of the modified proteins or polypeptides and the antiviral activity. The more negative the active substance, the greater is the antiviral activity, in particular the anti-HIV activity.

As already stated above, the "additional net negative charge" can be quantified on the basis of the retention time. This retention time is determined, for example, in accordance with the following chromatographic method:

- Prepare a solution of substance to be tested in a concentration of 1 mg/ml of a Tris.HCl buffer (0.02 M) having a pH of 7.5 (buffer A).
- Inject 100 µl of the sample into a FPLC system (Fast Protein Liquid Chromatography) from Pharmacia, Woerden, the Nether-

lands, which is provided with a mono-Q^R-HR 5/5 anion exchange column from Pharmacia.

- Elute at a rate of 0.25 ml/min using a gradient of 100% buffer A to 100% buffer B, consisting of buffer A + 1 M NaCl, in 30 minutes.
- Measure the retention time.

The "additional net negative charge" can also be quantified in another way, that is to say on the basis of the theoretical net negative charge. This theoretical value is calculated by multiplying the number of derivatised groups by the change in charge per derivatised group, plus the charge of the starting material. In the case of the negatively charged polypeptides or modified proteins according to the invention, the net negative charge will be lower than -60 and, for example, of the order of magnitude of -60 to -300 and below.

The criterion of the theoretical net negative charge is illustrated with reference to the following examples.

In the compound Suc-HSA (a reaction product of human serum albumin and succinic anhydride) which can be used according to the invention, all 61 positive NH₂ + of lysine have been replaced by negative COO⁻ groups. Thus, there is a change in charge of 2 per lysine. The theoretical charge of this compound is therefore: -15 (from the original albumin or HSA) + (2 × -61) = -137. For bovine serum albumin (BSA) the value for the Suc-BSA material would be -140 because the value of the charge on the original BSA is -15.

Suc-HSA, the reaction product of human serum albumin and succinic anhydride which can be used according to the invention, has a theoretical net negative charge of -137 (= -15 + 61 × -2).

Aco-HSA, the reaction product of human serum albumin and aconitic anhydride (anhydride of cis- or trans-prop-1-ene-1,2,3-tricarboxylic acid) which can be used according to the invention, has a theoretical net negative charge of -198 (= -15 + (61 × -2)).

The negative charge for the very stable reaction product of albumin and propane-1,2,3-tricarboxylic acid anhydride, which is to be preferred, is similar.

Moreover, the prolongation of the retention time compared with that of HSA, determined under the chromatography conditions

described, is 13 minutes for Aco-HSA and 11.5 minutes for Suc-HSA.

Moreover, the theoretical charge on the proteins/ polypeptides is calculated as the average of the charge on all amino acids present in the molecule (about 600 amino acids in the case of serum albumin).

It is also possible to introduce three or more carboxyl groups per amino group/basic group into the starting materials which can be used according to the present invention. Of course, active materials are then obtained which have an even higher negative charge and a prolongation of the retention time which is even greater than the abovementioned value.

The modified proteins or polypeptides which contain an additional net negative charge and can be used in the pharmaceutical preparations according to the invention are designated "negatively charged polypeptides" in the remainder of this description. Compounds of this type are generally water-soluble and they can exist in ionic form.

The negatively charged polypeptides are preferably poly-amino acids and modified plasma proteins, such as albumin and α -acid glycoproteins ("orosomucoid"). Polypeptides having a molecular weight of the order of magnitude of about 70,000 are suitable. However, the molecular weight can also be appreciably higher or lower; the important factor is that a poly-anionic polypeptide structure is present in the molecule.

It has been found that lysine and histidine are preferred as groups to be derivatised in the negatively charged polypeptides to be used according to the invention. The nitrogen-containing group in lysine is an amino group, whereas the nitrogen-containing group in histidine is regarded as an "other basic functional group". Moreover, for example, polylysine can also be used successfully according to the invention.

Standard chemicals which are capable of introducing an additional net negative charge into the starting material are used to prepare the derivative. Preferably, however, aldehydes, anhydrides, acid chlorides and iso(thio)cyanates are used. It has been found that reagents of this type yield negatively charged polypeptides which provide a pharmaceutical preparation with an outstanding

action against the abovementioned disorders and conditions.

-The following substances may be mentioned as examples of reagents for preparing derivatives of proteins or polypeptides.

1. Anhydrides

1.1. Straight-chain anhydrides


Give, by reaction with amines in proteins, amide bonds which are not protonated at a physiological pH.

$\text{NH}_3^+ \rightarrow$ neutral amide.

(change in charge of -1).


1.1.1. Symmetrical anhydrides:

Acetic anhydride




Propionic anhydride

Butyric anhydride




1.1.2. Asymmetric anhydrides:

Acetic propionic anhydride



Acetic butyric anhydride




1.2.1. Cyclic anhydrides

Give, by reaction with amines in proteins, amide bonds which are not protonated at a physiological pH and in addition they introduce a carboxyl group which is deprotonated at a physiological pH.

$\text{NH}_3^+ \rightarrow$ neutral amide + negative carboxyl group.

(change in charge of -2)

Succinic anhydride




6

Maleic anhydride

Glutaric anhydride

5 Phthalic anhydride



5

1.2.2. Cyclic anhydrides having an additional carboxyl group in the ring.

10 Give, by reaction with amines in proteins, amide bonds which are not protonated at a physiological pH and in addition they introduce two carboxyl groups which are deprotonated at a physiological pH.


10

$\text{NH}_3^+ \rightarrow$ neutral amide + 2 negative carboxyl groups.

15 (change in charge of -3).

15

cis- or trans-aconitic anhydride



20 Citric anhydride

20

Isocitric anhydride

25 2. Acid halides (in general acid chlorides).

25

Give, by reaction with amines in proteins, amide bonds which are not protonated at a physiological pH.


$\text{NH}_3^+ \rightarrow$ neutral amide.

(change in charge of -1).


30

30


Acetyl fluoride



Acetyl chloride




35 Acetyl bromide



35

Propionyl chloride



		7	$= \text{CH}_3 - \text{CH}_2 - \text{CH}_2 - \overset{\text{O}}{\underset{\text{Cl}}{\text{C}}}$
	Butyryl chloride		
			$= \text{CH}_3 - (\text{CH}_2)_{16} - \overset{\text{O}}{\underset{\text{Cl}}{\text{C}}}$
	Stearyl chloride		
5	Phosgene (carbonyl chloride)		$= \text{Cl} - \overset{\text{O}}{\underset{\text{Cl}}{\text{C}}} - \text{Cl}$
	Benzenesulphonyl chloride		$= \text{C}_6\text{H}_5 - \overset{\text{O}}{\underset{\text{O}}{\text{S}}} - \text{Cl}$
	Chlorosulphonic acid		$= \text{HO} - \overset{\text{O}}{\underset{\text{O}}{\text{S}}} - \text{Cl}$

10

The last two give a change in charge of -2 because, in addition to the removal of the positive charge from the amino group, a negative charge is introduced on the sulphonyl group.

3. Aldehydes

15


Give imines by reaction with amines in proteins.

$\text{NH}_3^+ \rightarrow$ neutral imine.


(change in charge of -1).

20


Formaldehyde



Acetaldehyde




Propionaldehyde




25


Butyraldehyde



Valeraldehyde



Caproaldehyde



30

4. Isothiocyanates


Give, by reaction with amines in proteins, thiocarbamyl bonds which are not protonated at a physiological pH.

$\text{NH}_3^+ \rightarrow$ neutral thiocarbamyl.


35

(change in charge of -1).


Benzene isothiocyanate




Fluorescein isothiocyanate



Rhodamine isothiocyanate



para-Isothiocyanatophenyl
sugar derivatives




5. Isocyanates

Give, by reaction with amines in proteins, urea bonds which are not protonated at a physiological pH.

$\text{NH}_3^+ \rightarrow$ neutral urea.

(change in charge of -1).

Benzene isocyanate



The abovementioned reagents for obtaining poly-anionic proteins or polypeptides are far from complete and give only a few examples from the various groups.

In the case of all reagents, additional anionic functional groups, such as phosphates, sulphates and carboxyl groups, can, where possible, be incorporated in the chain in such a way that additional negative charges are introduced.

Because the additional net negative charge on the polypeptides which are used according to the invention is very important for the action, the starting protein or starting polypeptide preferably contains as many groups as possible which can be derived and thus acquire an additional negative charge. Preferably, the natural or synthetic oligopeptides, which are used as starting materials, consist to the extent of more than 5%, in particular more than 15% and even more particularly more than 25% of amino acids which contain functional amino groups or other functional basic groups, for example the abovementioned lysine and histidine.

The preparations according to the invention can be administered enterally or parenterally. Preparations which can be administered parenterally or enterally can also be prepared from

preparations according to the invention.

Medicinal preparations which contain the negatively charged polypeptides according to the invention can be in the form of powders, suspensions, solutions, sprays, emulsions, ointments or creams and can be used for topical application, for intranasal, rectal or vaginal administration, and also for oral or parenteral (intravenous, intradermal, intramuscular, intrathecal, and the like) administration. Such preparations can be prepared by combining the negatively charged polypeptides (for example by mixing, dissolving or the like) with pharmaceutically acceptable excipients of a neutral type, such as aqueous or non-aqueous solvents, stabilisers, emulsifiers, detergents and additives, and also, if desired, with colorants and aroma substances. The concentration of the negatively charged polypeptide in the preparation according to the invention can vary substantially and be between 0.001, preferably 0.1, and 100%, depending on the mode of administration. Furthermore, the dose of the negatively charged polypeptide to be administered can, for example, be between 0.1 mg and 100 mg/kg of body weight.

The invention also relates to the use of substances which have acquired an additional net negative charge, as defined above, as active substance or as substance contributing to the action, or as carrier for active substance when preparing pharmaceutical preparations which are suitable for treating or curing viral infections and immunodeficiency diseases such as retrovirus infections, including AIDS and AIDS-related diseases, and which can be used to inhibit fusion of infected with non-infected cells.

The invention also relates to a method for treating diseases or disorders caused by retrovirus infections such as AIDS and AIDS-related diseases, or conditions in which fusion of virus with cells or fusion of virus-infected cells with non-infected cells occurs, with which method an additionally negatively charged protein or polypeptide as defined above is used.

The invention also relates to a method for the preparation of modified proteins and polypeptides, with which method the amino groups and/or other basic functional groups of the proteins or polypeptides are derivatised with a reagent which prevents protonation of basic amino acids, the proteins or polypeptides acquiring an

additional net negative charge such that the prolongation of the retention time of the protein or polypeptide derivative compared with that of the protein or polypeptide not converted to a derivative is at least 9 minutes, the retention time being determined by means of FPLC on an anion exchange column.

The invention also relates to the new modified proteins or polypeptides, comprising a protein or polypeptide in which the amino groups and/or other basic functional groups have been reacted with a reagent which prevents protonation of the basic amino acids and/or other basic groups or replaces said basic amino acids and/or other basic groups by one or more functional groups having a negative charge, the modified protein or polypeptide having an additional net negative charge, compared with the non-modified protein or polypeptide, such that the prolongation of the retention time of the protein or polypeptide derivative, compared with that of the protein or polypeptide not converted to a derivative, is at least 9 minutes, the retention time being determined by means of FPLC on a column containing an anion exchanger.

According to the invention, it has been found that negatively charged polypeptides are, inter alia, powerful and selective anti-HIV agents which substantially reduce syncytium formation and virus-cell fusion, do not bind to the OKT4A epitope of the CD4 receptor and have only a slight inhibitory action on the interaction of anti-gp120 and mAb gp120 and the binding of virus cells at very low concentrations. The negatively charged polypeptides used or prepared according to the invention have no or only a low toxicity.

The invention is illustrated with reference to the investigation described below.

Investigation

Preparation of negatively charged albumin with the aid of formaldehyde and succinic anhydride (form-HSA and suc-HSA).

500 mg of HSA were dissolved in 50 ml of 0.2 M Na_2CO_3 (pH 10.0), formaldehyde was added to give a final concentration of 20% by weight, based on the starting material, and the solution formed was stirred in the dark for 72 hours at room temperature. In order to remove insoluble material, the solution was filtered through a filter with 0.2 μm openings, purified on a Sephadex G25 column.

washed with distilled water on a PM10 membrane in an Amicon "Stirred Cell Concentrator" and finally lyophilised, form-HSA being obtained.

500 mg of HSA were dissolved in 50 ml of 0.2 M K_2HPO_4 (pH 8.0). 500 mg of solid succinic anhydride were added and the solution was stirred until the succinic anhydride had dissolved. The pH was kept between 8.0 and 8.5 using 6 M sodium hydroxide. Purification was carried out as described for form-HSA. Pure suc-HSA was obtained.

The additional net negative charge of the modified albumin was determined with the aid of a FPLC system (Fast Protein Liquid Chromatography) from Pharmacia, Woerden, the Netherlands, using a mono-Q anion exchange column from Pharmacia. Buffer A was a 0.02 M Tris.HCl buffer (pH 7.4) and buffer B consisted of buffer A plus 1 M NaCl. Elution was carried out at a rate of 0.25 ml/min, using a gradient of 100% A to 100% B in 30 minutes. The samples of the substance to be investigated were dissolved in an amount of 1 mg/ml in buffer A and in each case 100 μ l were injected into the FPLC system.

MT-4 cells from a T_4 lymphocyte cell line carrying HTLV-I were used for the anti-HIV-1 test. The MT-4 cells were cultured in RPMI 1640 medium, supplemented with 10% by volume of heat-inactivated fetal calf serum (FCS) and 20 μ g/ml of gentamicin. MOLT-4 cells (clone 8, cf. J.Virol. 57, 1159-1162) were used for the test relating to syncytium formation. The cells were kept in a moist atmosphere of 5% CO_2 in air at a temperature of 37°C. Every 3-4 days cells were centrifuged down and transferred to new culture flasks (2×10^5 cells/ml). The cells were analysed periodically for the presence of mycoplasma: they were always found to be free from mycoplasma.

HIV-1 (strain HTLV-III_B) was obtained from the culture fluid of HUT-78 cells infected with HIV-1. The virus titre of the culture fluid was determined in MT-4 cells. The virus was stored at -70°C.

The antiviral activity of the negatively charged polypeptides was determined on the basis of the inhibitory effect on virus-induced cytopathogenicity in MT-4 cells and was recorded with the aid of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method, which is described in J.Virol. Methods 20.

309-321.

Syncytium formation was determined as follows. The modified polypeptides were diluted in RPMI and transferred to the wells of microtitre plates. 5×10^4 HIV-1-infected HUT-78 cells, which had previously been washed twice in order to remove free virus particles, were then added to the wells, immediately followed by the addition of 5×10^4 MOLT-4 cells, a final volume of 200 μ l being obtained. The cell mixtures were cultured at 37°C in a CO₂-containing cell incubator. The first syncytia were formed after 4-6 hours. After 24 hours the cells were analysed by microscopic examination and laser flow cytofluorography.

The assay relating to virus adsorption was carried out as follows.

MT-4 cells were exposed to HIV-1 virions in the absence or the presence of the negatively charged polypeptides according to the invention. After incubation for 30 minutes at 37°C, the cells were washed in order to remove non-bound virus particles. The cells were then stained for indirect fluorescence using polyclonal antibody for HIV-1, and the HIV-1 particles bound to the cells were analysed by laser flow cytofluorography.

The CD4 immunofluorescence assay was carried out using the method described in No. 42 Proc.Natl.Acad.Sci. USA 86, 3322-3326. MT-4 cells were incubated for various periods at room temperature in the absence and the presence of a negatively charged polypeptide. The cells were then stained with optimum concentrations of the monoclonal antibodies OKT4A-FITC (orthodiagnostics) or anti-leu3a-PE and "Simultest immuno monitoring" with control material (FITC-labelled IgG₁ and PE-labelled IgG₂) (Becton Dickinson) for 20 minutes at 4°C, washed once in PBS and fixed in 0.5 ml of 0.5% by weight paraformaldehyde in PBS.

The investigations described above showed that a clear correlation exists between the antiviral activity and the negative charge. For example, by simple succinylation of the lysine groups of albumin an anionic compound is obtained which has a very low IC₅₀ (1 μ g/ml). None of the negatively charged polypeptides tested was found to be cytotoxic at concentrations of up to 1000 μ g/ml.

The Aco-HSA material was prepared analogously to the method

described above. The anti-HIV activity of this material is very high: $IC_{50} = 0.0056 \mu\text{g/ml}$. This compound is therefore 175 times more active than Suc-HSA and is one of the most active compounds known at present (approximately 25 times more active than AZT).

5 The negatively charged polypeptides according to the invention inhibit the virus adsorption to only a slight degree, for example in a concentration of $100 \mu\text{g/ml}$. For comparison: dextran sulphate inhibited virus adsorption virtually completely at a concentration of $25 \mu\text{g/ml}$.

10 The syncytium formation is appreciably reduced by the negatively charged polypeptides according to the invention, for example by 50% at a concentration of only about $2 \mu\text{g/ml}$. In order to obtain a similar inhibition with, for example, dextran sulphate, a concentration of $28 \mu\text{g/ml}$ is needed, which amount is about 50 times higher than the IC_{50} thereof in the antiviral assay ($0.6 \mu\text{g/ml}$).

15 It is known that OKT4A mAb binds to an epitope of the CD4 molecule, which is responsible for the HIV adsorption and can prevent binding of HIV particles to the cells. Aurintricarboxylic acid (ATA) gives specific interaction with this epitope of the CD4 molecule and was used as positive control. The OKT4A mAb-CD4 interaction was completely inhibited by ATA in a concentration of $25 \mu\text{g/ml}$. The negatively charged polypeptides according to the invention (and also dextran sulphate) had no influence on this interaction in concentrations of up to $100 \mu\text{g/ml}$, from which it can be concluded that the active substances according to the invention do not bind to this epitope of the CD4 receptor.

25 Persistently HIV-1-infected HUT-78 cells and a specific anti-gp120 mAb, which recognises the V3 region of gp120 and which plays an important role in the formation of giant cells, were used in the investigation of the direct interaction of the negatively charged polypeptides with the viral gp120. Dextran sulphate inhibited the binding of anti-gp120 mAb to gp120 in a manner which is dependent on the concentration, the amounts involved being said to be equal to the amounts which have an antiviral action. The negatively charged polypeptides according to the invention also inhibit the anti-gp120-mAb-gp120 interaction in a manner which is dependent on the concentration. However, the concentration which is needed for a 50%

inhibition is many times (for example 100 times) greater than the IC_{50} , from which it can be concluded that shielding of gp120 is probably not the only mechanism of action of the compounds according to the invention.

The mechanism of action of the compounds according to the invention is based on preventing the fusion of the virus with the cells and with a compound from the fusion of infected cells with non-infected cells. Very probably, the interaction of the compounds with viral fusion proteins (such as GP41 in the case of HIV) is essential here. This mechanism of action has never been described before.

Procedure for and results of further experiments relating to anti-viral and anticoagulant action

Reference is made to the appended Tables 1, 2, 3 and 4.

The antiviral activity of two substances according to the invention (Aco-HSA and Suc-HSA) against viruses causing immunodeficiency is compared with the activity of dextran sulphate, another polyanionic antiviral compound. Conclusion: substances according to the invention are active against HIV-1, HIV-2, FIV and SIV.

The anti-HIV-1 test has already been described above.

HIV-2 (LAV-2_{ROD}) (obtained from Dr. L. Montagnier, Paris, France) was isolated from the medium supernatant of persistently LAV-2_{ROD}-infected MOLT-4 cells. The anti-HIV-2 test is identical to the anti-HIV-1 test.

FIV-48 and FIV-113 were isolated from peripheral mononuclear blood cells of seropositive wildcats. The anti-FIV test was carried out using the method of

Egberink et al. (Proc.Natl.Acad.Sci. USA (1990) 87: 3087-3091).

Mitogen-stimulated cat thymocytes were plated out in 1.6 cm² wells (10⁶ cells per ml) in the presence of various concentrations of the substances to be tested. After incubating for 1 hour at 37°C, FIV was added in an amount which corresponds to 6 x 10⁶ cpm reverse transcriptase (RT) activity. After incubating for 1 hour at 37°C, the medium was replaced by fresh medium containing various concentrations of the substances to be tested. The RT activity in the

the supernatant was determined after incubating for 4 and 6 days at 37°C
is (see Table 2).
ing

The antiviral activity of two substances according to the
invention (Aco-HSA and Suc-HSA) against DNA viruses is compared with
the activity of dextran sulphate, another polyanionic antiviral
compound. Conclusion: the substances according to the invention have
no activity against the DNA viruses tested, in contrast to dextran
sulphate.

Anti-CMV test: human embryonic lung (HEL) fibroblasts were
cultured in MEM medium to which 10% fetal calf serum, 1% L-glutamine
and 0.3% sodium bicarbonate were added. The cells were infected with
100 PFU (plaque forming units) of human cytomegalovirus (CMV, strain
AD169 and Davis strain). At the same time, the substances to be
tested were added in various concentrations. The virus plaque
formation and the cell death caused by the virus were determined as
described by Snoeck et al. (1988) 32, 1839-1844 (see Table 2).

The antiviral activity of two substances according to the
invention (Aco-HSA and Suc-HSA) against RNA viruses is compared with
the activity of dextran sulphate, another polyanionic antiviral
compound. Conclusion: The substances according to the invention have
no activity against the RNA viruses tested except for influenza. In
contrast, dextran sulphate has an activity only against VSV and
Sindbis virus.

The activity of the substances against polio virus, Coxsackie
virus, VSV, Sindbis, Semliki Forest virus, reovirus, para-influenza
virus, HSV-1, HSV-2 and VMW was determined in the following way:

Confluent cell cultures (Vero cells, HeLa cells and primary
rabbit kidney cells) were inoculated with the various viruses to 100
times the CCID₅₀ (50% cell culture infective dose) in the presence of
various concentrations of the substances to be tested. After 1 hour
the medium was replaced by medium in which only the substances to be
tested are still present in various concentrations. The cell death
caused by the viruses was determined after 1 to 2 days post-
infection for VSV; after 2 days for Coxsackie virus, Semliki Forest
virus and polio virus; after 2 to 3 days for HSV-1, HSV-2 and
Sindbis virus; and after 6 days for para-influenza virus and reo-
virus.

The activity of the substances to be tested against Sendai virus and influenza virus was determined by measuring the fusion of the viral membrane with erythrocyte ghosts and liposomes and with BHK-21 cells or LLC-MK₂D cells. The R₁₅-dequenching method as described by Hoekstra et al. (1984), Biochemistry 23, 5675-5681 and Wildschut et al. in Molecular Mechanisms of Membrane Fusion, (S. Ohki, D. Doyle, T.D. Flanagan, S.W. Hui and E. Mayhew, editors) 1988, Plenum Press, New York, pp. 441-450 was used for this purpose.

To summarise: influenza virus and Sendai virus were labelled with R₁₅. This resulted in a 70% self-quenching of the fluorescence. 35 µl of a concentrated suspension of R₁₅-labelled virus were introduced into a cuvette containing liposomes and erythrocyte ghosts of various cells (in HEPES buffer) and the increase in fluorescence (dequenching) caused by the fusion was measured on-line (excitation 560 nm, emission 590 nm). The same procedure was carried out in the presence of various concentrations of the substances to be tested.

Other polyanionic antiviral compounds such as dextran sulphate and heparin have a serious anticoagulant activity as a significant negative side effect. The substances according to the invention do not have this side effect. Only Aco-HSA has a slight anticoagulant activity at high concentrations of, for example, 100 µg/ml (that is more than 10,000 x the antiviral concentration).

Table 1

Inhibitory effect (IC₅₀ µg/ml) of polyanionic compounds on retroviruses

	HIV-1	HIV-2	FIV	SIV
Suc-HSA	0.9	78	< 0.1	+
Aco-HSA	0.025	5.9	< 0.01	+
DS	0.6	0.08	ND	ND

+ = activity determined

ND = not determined

Table 2

Inhibitory effect (IC₅₀ µg/ml) of polyanionic compounds on DNA viruses

HSV-1	HSV-2	HSV field	VMW	CMV
-------	-------	-----------	-----	-----

TK-

5	Suc-HSA	>400	>400	ND	ND	>400
	Aco-HSA	>400	>400	>400	>400	>400
	DS	0.7	1.0	2.0	2.0	0.2

Table 3

Inhibitory effect (IC₅₀ µg/ml) of polyanionic compounds
on the replication of RNA viruses

Virus	ACO-HSA		DS	
Coxsackie	>400		>400	
Polio	>400		>400	
VSV	>400		7.0	
Sindbis	>400		2.0	
Semliki Forest	>400		>400	
Reo-virus	>400		>400	
para-influenza	>400		>400	
influenza	0.8		>400	
Sendai	>400		>400	

Table 4

Anticoagulant action of the compounds,
determined as APTT (sec)

Conc. (µg/ml)	Dextran sulphate	Suc-HSA	Aco-HSA	Heparin
100	>400	37.7	51.1	>400
50			42.0	
30			37.8	
20			35.1	
10	69.4	33.0	33.0	220
5	49.0	37.2	36.2	140
3	43.6	35.8	35.9	65
1	37.4	36.2	37.0	40.5
0.1	37.6	38.0	37.8	40.3
0.01	38.0	39.0	36.8	38.4

The compounds were dissolved in PBS of pH 7.2 and 30 μ l were added to 270 μ l of plasma.

As control, 30 μ l of PBS were added to 270 μ l of plasma, which resulted in an APTT value of 38.0 sec.

5 APTT = activated partial thromboplastin time (seconds)

5

APTT was determined electromechanically using standard methods.

10

15

20

25

30

35

C L A I M S

1. Pharmaceutical preparations which are suitable for treating or curing viral infections, including influenza, and immunodeficiency diseases such as retrovirus infections, including AIDS and AIDS-related diseases, and which can also be used to inhibit fusion of virus-infected cells with non-infected cells, which preparations contain modified proteins or polypeptides as active substance or substance contributing to the action or as carrier for other substances, which are also active, which modified proteins or polypeptides have acquired an additional net negative charge by derivatisation of their amino groups and/or other basic functional groups with a reagent which prevents protonation of basic amino groups and/or other basic functional groups or a reagent which replaces the said basic groups by one or more functional groups having a negative charge, the prolongation of the retention time of the protein or polypeptide derivative compared with that of the protein or polypeptide not converted to a derivative being at least 9 minutes, the retention time being determined by means of FPLC on an anion exchange column.
2. Preparations according to Claim 1, the groups to be derived being lysine and histidine residues and the reagent being chosen from aldehydes, anhydrides, acid chlorides and iso(thio)cyanates.
3. Preparations according to Claim 1, the amino acids of the protein or the polypeptide consisting to the extent of more than 5%, preferably more than 15% and in particular more than 25% of amino acids containing functional amino groups or basic groups.
4. Preparations according to Claims 1-3, the modified protein or polypeptide having been obtained from polyamino acids and modified plasma proteins such as albumin and α -acid glycoprotein.
5. Preparations according to Claims 1-4, the protein to be converted to a derivative being serum albumin and the reagent being cis-aconitic anhydride.
6. Preparations according to Claims 1-5, which can be administered enterally or parenterally or can be processed to give preparations which can be administered enterally or parenterally.
7. Preparations according to Claims 1-6, in which the active substances which have acquired an additional net negative charge are

present in an amount of 0.1-100%.

8. Use of substances which have acquired an additional net negative charge, as defined in one or more of the preceding claims, as active substance or substance contributing to the action, or as carrier for active substance when preparing pharmaceutical preparations which are suitable for treating or curing viral infections and immunodeficiency diseases such as retrovirus infections, including AIDS and AIDS-related diseases, and which can be used to inhibit fusion of infected with non-infected cells.

9. Method for treating diseases or disorders caused by retrovirus infections such as AIDS and AIDS-related diseases, or conditions in which fusion of virus with cells or fusion of virus-infected cells with non-infected cells occurs, with which method an additionally negatively charged protein or polypeptide as defined in one or more of the preceding Claims 1-7 is used.

10. Method for the preparation of modified proteins and polypeptides, characterised in that the amino groups and/or other basic functional groups of the proteins or polypeptides are derivatised with a reagent which prevents protonation of basic amino groups and/or other basic groups, or a reagent which replaces the said basic groups by one or more functional groups having a negative charge, the proteins or polypeptides acquiring an additional net negative charge such that the prolongation of the retention time of the protein or polypeptide derivative compared with that of the protein or polypeptide not converted to a derivative is at least 9 minutes, the retention time being determined by means of FPLC over an anion exchange column.

11. Modified protein or polypeptide, comprising a protein or polypeptide in which the amino groups and/or other basic functional groups have been reacted with a reagent which prevents protonation of the basic amino acids and/or other basic groups or a reagent which replaces the said basic groups by one or more functional groups having a negative charge, the modified protein or polypeptide having an additional net negative charge, compared with the non-modified protein or polypeptide, such that the prolongation of the retention time of the protein or polypeptide derivative, compared with that of the protein or polypeptide not converted to a

derivative, is at least 9 minutes, the retention time being determined by means of FPLC on an anion exchange column.

it

is

is

is

nd

ng

it

or

or

s-

an

in

y-

ic

ed

ps

id

ve

et

of

he

9

ver

or

nal

ion

ent

nal

ide


on-

the

red

a

International Publication No

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC Int.C1.5 A 61 K 37/02 C 07 K 3/08 C 07 K 15/00		
II. FIELDS SEARCHED Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.C1.5	A 61 K C 07 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	EP,A,0406416 (MEIJI MILK PRODUCTS CO., LTD) 9 January 1991, see the whole document -----	1-11
¹⁰ Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search 11-06-1992		Date of Mailing of this International Search Report 15. 07
International Searching Authority EUROPEAN PATENT OFFICE		Signature of Authorized Officer 

INTERNATIONAL SEARCH REPORT

International application No.

PCT/NL 00036

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 9
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 9 is directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

This annex I
The member
The Europe

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

NL 9200036
SA 57441

sons:

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 01/07/92
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0406416	09-01-91	AU-A- 2937489	01-08-90
		JP-A- 2275824	09-11-90
		WO-A- 9007340	12-07-90

P.F. () P () R M 10479

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

